Statistical Considerations for Clinical Trials During COVID-19: Unplanned Changes in Estimands with Two-Stage Adaptive Designs, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Background, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part III), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part I), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: An Adaptive Hybrid Design for Clinical Development in Rare Diseases, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: A Two-Stage Adaptive Design for Clinical Trials in Patients with COVID-19 High Risks, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Accurate COVID-19 Testing in Clinical Trials, Stephan Ogenstad, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part II), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: A Two-Stage Adaptive Design for Clinical Trials with Chronic Conditions, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part II), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part III), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Impacts on Minimization Randomization and Mitigations, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part I), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Impacts on Permuted Block Randomization and Mitigations, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Independent DMC for Blinded Data Monitoring and Analysis, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Integrated Analysis of Efficacy (IAE) with Adaptive Estimands, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Interim Analysis with Adaptive Estimands Based, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis (Part I), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis (Part III), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis (Part II), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Phase 1 Cancer Trials, Michael T. Tirgan, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Steps for Mitigation, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Impacts on Minimization Randomization and Mitigations, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part I), Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part II), Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part III), Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part II), Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Steps for Mitigation, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Integrated Analysis of Efficacy (IAE) with Adaptive Estimands, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Interim Analysis with Adaptive Estimands Based, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: An Adaptive Hybrid Design for Clinical Development in Rare Diseases, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: A Two-Stage Adaptive Design for Clinical Trials with Chronic Conditions, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis (Part I), Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis (Part II), Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis (Part III), Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: A Two-Stage Adaptive Design for Clinical Trials in Patients with COVID-19 High Risks, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part III), Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Accurate COVID-19 Testing in Clinical Trials, Stephan Ogenstad, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Phase 1 Cancer Trials, Michael T. Tirgan, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Independent DMC for Blinded Data Monitoring and Analysis, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Impacts on Permuted Block Randomization and Mitigations, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Background, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part I), Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Unplanned Changes in Estimands with Two-Stage Adaptive Designs, Qing Liu, Karl E. Peace
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications